BMS-906024 is a drug with a benzodiazepine structure, developed by Bristol-Myers Squibb and disclosed at the spring 2013 American Chemical Society meeting in New Orleans to treat breast, lung, colon cancers and leukemia.[1] The drug works as a pan-Notch inhibitor. The structure is one of a set patented in 2012,[2] and is being studied in clinical trials.[3][4][5]
^WO 2012129353, Quesnelle C, Kim SH, Lee F, Gavai A, "Bisfluoroalkyl-1,4-Benzodiazepinone Compounds", published 27 September 2012, assigned to Bristol-Myers Squibb Company